ArticlePeerJ2026
Clinical efficacy analysis of high-intensity focused ultrasound ablation in treating fibroadenomas of different breast gland types: a retrospective study.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-Intensity Focused Ultrasound (HIFU) is an emerging non-invasive therapy for breast fibroadenoma. However, its efficacy across different breast glandular types, which may influence acoustic energy deposition, remains underexplored. Objective: This study sought to investigate the treatment efficacy of ultrasound (US)-guided HIFU for breast fibroadenoma with respect to different breast gland types. Methods: A retrospective analysis was conducted on 201 patients (314 lesions) with biopsy-confirmed breast fibroadenomas treated between January 2024 and November 2024. Patients were stratified into four groups based on the American College of Radiology (ACR) breast composition classification: fatty group (<25% glandular tissue), loose group (25-50%), mixed group (51-75%), and dense group (>75%). All patients underwent ultrasound-guided HIFU ablation using the JC-200 system (Chongqing Haifu Medical Technology Co., Ltd., China). The baseline characteristics of patients, lesion features of fibroadenomas, relevant parameters during HIFU treatment, follow-up duration, and tumor volume reduction rate (VRR) were recorded and comparatively analyzed. Statistical analyses included One-Way Analysis of Variance (ANOVA) with least significant difference (LSD)-t tests for pairwise comparisons. Results: The average surgical power in the loose group (142.8 ± 38.5 W) was significantly higher than that in the fatty group (128.7 ± 23.3 W), mixed group (128.8 ± 36.6 W), and dense group (121.4 ± 39.5 W), with statistically significant differences ( Conclusion: HIFU is a safe and effective treatment for fibroadenomas across different breast gland types. The significantly superior VRR in fatty-type breasts underscores the critical role of preoperative breast gland typing in predicting HIFU outcomes. These findings advocate for the integration of breast density assessment into clinical decision-making to optimize individualized HIFU treatment planning for benign breast tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.